9^th World Biomarkers Congress December 07-08, 2017 Madrid, Spain

Conference Series invites all the participants from all over the world to attend '9^th World Biomarkers Congress ' to be held on December 07-08, 2017 at Madrid, Spain which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.

World Biomarkers 2017 is a platform to discuss and learn about the latest advancements in the field of Molecular and Cancer Biomarkers and their journey from labs to industry scale production. Biomarkers have been a great tool in the new generation diagnosis, prognosis and treatment of various diseases. Biomarkers include proteins, lipids, DNA, RNA and several other components in the body. Their applications in some disease pathologies have gained a prominence over period like in cancer and Alzheimer’s diseases. Advanced studies in these fields also opened up a wide scope in development of medical tools and technologies like imaging and companion diagnostics. People form American Oncology society and European Oncology society have been doing research in the field of biomarkers.

Conference Series  the host of this conference is comprised of 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+Workshops on diverse Medical, Pharmaceutical, Clinical, Engineering, Science, Technology, Business and Management field is organizing conferences all over the globe

Track 1: Biomarkers

A biomarker can be anything that can be accurately measured as an indicator of normal biological functioning, pathogenic paths or a drug response to a therapeutic drug intervention.  Biomarkers are the biomarker usually in molecular form.Biomarkers take part in various purposes, including disease diagnosis and prognosis, prediction and calculation of treatment response, and safety evaluation. The  biomarkers are exclusively being developed and validated to be used in drug development, and used to support approval of drug products.

Biomarkers are mainly classified into Protein biomarkers, Nucleic acid based biomarkers, Lipid biomarkers and Small molecule biomarkers. Almost every pharmaceutical company has been developing  biomarker programs. There has been a rapid increase in the number of Biomarkers Congress used in drug delivery over the last decade.

Related Biomarkers Conferences | Cancer Biomarkers Conferences | Molecular Biomarkers Conferences

 8^th Biomarkers Conference, December 05-07, 2016 Philadelphia, USA; Biomarkers & Immuno-Oncology World Congress May 2-4,2017, Philadelphia, PA, 9^th Genomics Conference, July 13-14, 2017, Chicago, USA; 9^th Pharmacogenomics Conference, July 13-14, 2017, Chicago, USA; 7^th Proteomics Conference, October 24-26, 2016, Rome, Italy; 19^th World Cancer Conference, November 21-23, 2017, London, UK; 12^th Annual Biomarkers Congress February 21-24, 2017, Manchester, UK; 13^th Annual Biomarkers & Diagnostics World Congress May 2-4, 2017, Philadelphia, USA; 2^nd Biomarkers Conference February 06-07, 2017, San-Diego, USA; 19^th International Conference on Biomarkers and Clinical Medicine, May 18-19, 2017, Paris, France; American Association for Cancer Research Annual Meeting April 01-05, 2017, Washington DC, USA; ESMO 2017 Congress, September 08-12, 2017, Madrid, Spain; European Society for Medical Oncology 2016 Congress October, 07-11, 2016 Denmark.

Track 2: Cancer Biomarkers

A cancer biomarker is an element or procedure that indicates the presence of cancer in the body. A biomarker may be any molecule released by presence a tumor or a specific indication of the body to the presence of cancer. Cancer biomarkers are usually biological molecules found in blood, other body fluids, or tissues that are a sign of a normal or abnormal process, or of a condition or disease.

Cancer biomarkers can be classified into Nucleic acid based biomarkers, Pathological biomarkers, In silico biomarkers, Imaging biomarkers and Glycoprotein biomarkers based on their structure and functioning. All these topics are discussed in these cancer biomarker conferences.

Related  Biomarkers Conferences | Cancer Biomarkers Conferences | Molecular Biomarkers Conferences

2^nd Cancer Diagnostics Conference, May 8-10, 2017, Barcelona, Spain; 6^th Mass Spectrometry Conference, September 25-27, 2017, Atlanta, USA; 5^th Mass Spectrometry Conference, December 12-14, 2017, Kuala Lumpur, Malaysia; 5^th Medicinal Chemistry Conference, December 05-07, 2016, Phoenix, USA; 5^th Computer Aided Drug Designing Conference, December 05-07, 2016, Phoenix, USA; 4^th International Oncology Conference, September 29-30, 2016, Abu Dhabi, UAE; 8^th UAE Cancer Congress, October 20-22, 2016, Dubai, UAE; American Thoracic Society Conference, May 19-24, 2017, Washington DC, USA; 17^th World Conference on Lung Cancer December, 04-07, 2016 Austria; 5th Emirates Oncology Conference, November 17-19, 2016, Abu Dhabi, UAE; European Society for Medical Oncology 2016 Congress October, 07-11, 2016 Denmark; ASCO Annual Meeting, June 02-06, 2016, Chicago, USA; 25th AICR Research Conference, November 14-16, 2016, North Bethesda, USA.

Track 3: Clinical biomarkers

Biomarkers which are used for clinical purposes are called clinical biomarkers. Clinical biomarkers along with Pathological biomarkers provide a vibrant and influential methodology to understanding the range of many diseases with uses in judgemental and analytic epidemiology, arbitrary clinical trials, screening for drugs or disease diagnosis and prognosis. Defined as changes in the constituents of cells or body fluids, these clinical biomarkers offer the means for standardized classification of a disease and risk factors, and the can extend the base information about the underlying pathogenesis of disease.

The main researches in clinical biomarkers are done in the fields of drug discovery, oncology, pharmacogenomics and disease diagnostics. This biomarker meeting goes in detail about these fields.

Related Biomarkers Conferences | Cancer Biomarkers Conferences | Molecular Biomarkers Conferences

3^rd Biologic Drugs Conference, June 19-21, 2017 Philadelphia, USA; 3^rd Genetic Engineering Conference, October 30-November 1, 2017, Las Vegas, USA; 3^rd Protein Engineering Conference, October 30-November 1, 2017, Las Vegas, USA; 7^th Personalized Medicine Conference, October 23-25, 2017 Chicago, USA; 7^th Molecular Diagnostics Conference, October 23-25, 2017 Chicago, USA; Philippine Cancer Society; European Organisation for Research and Treatment of Cancer; American Society of Clinical Oncology; 5th Emirates Oncology Conference, November 17-19, 2016, Abu Dhabi, UAE; American Academy of Neurology Annual Meeting April 22-28, 2017, Boston, USA;  4^th Caribbean Biomedical Research Days Conference, January 16-18, 2017, Rodney Bay, St. Lucia; Biomarkers & Precision Medicine USA Congress 2016, October 03-04, 2016, San Diego, USA; 3^rd Annual Drug Discovery USA Congress, 3-4 October 2016, San Diego, USA.

Track 4: Biomarkers and Cancers

Biomarkers play a significant role in cancer prognosis, diagnosis and treatment of cancers these days. There are many types of cancers which are hard to even diagnose. The latest designed biomarkers and their applications provide a great advantage in these cases. Cancer Epidemiology, treatment and latest research is greatly relayed on the biomarkers.

The major types of cancers in which biomarkers are widely being used are breast cancer, lung cancer, prostate cancer and blood cancer. Cancer biomarkers conferences provide a good platform for elaborated discussion on various new researches.

Related Biomarkers Conferences | Cancer Biomarkers Conferences | Molecular Biomarkers Conferences

Biomarkers & Immuno-Oncology World Congress May 2-4,2017, Philadelphia, PA, Medical Imaging Conference, October 20-21, 2016 Chicago, USA; 6^th Radiology Conference, October 19-20, 2017, New York, USA; 6^th Imaging Conference, October 19-20, 2017, New York, USA; 5^th Euro-Global Experts Meeting on Medical Case Reports, September 7-9, 2017, Paris, France; 4^th Clinical Case Reports Meeting, April 17-19, 2017, Dubai, UAE; 25th AICR Research Conference, November 14-16, 2016, North Bethesda, USA; National Cancer Institute; Philippine Cancer Society; European Organisation for Research and Treatment of Cancer; 5th Emirates Oncology Conference, November 17-19, 2016, Abu Dhabi, UAE; American Academy of Neurology Annual Meeting April 22-28, 2017, Boston, USA;  4^th Caribbean Biomedical Research Days Conference, January 16-18, 2017, Rodney Bay, St. Lucia; Biomarkers & Precision Medicine USA Congress 2016, October 03-04, 2016, San Diego, USA; 3^rd Annual Drug Discovery USA Congress, 3-4 October 2016, San Diego, USA.

Track 5: Biomarkers and Non-cancerous diseases

Biomarkers plan an important role in various neurological and cardiovascular diseases. The diseases which are incurable from ages are being offered a possible treatment and easy diagnosis with the help of advancements in biomarkers through different diagnostics and imaging technologies. Cardiac biomarkers and neuro biomarkers has brought a great revolution in disease diagnosis and prognosis.

Biomarkers are used in many other non-cancerous diseases. Some of the important ones are Alzheimer’s disease, Neurodegenerative diseases, cardiovascular diseases, and Huntington's disease. 

Related Biomarkers Conferences | Cancer Biomarkers Conferences | Molecular Biomarkers Conferences

6^th Experts Meeting on Medical Case Reports, October 16-18, 2017, San Francisco, USA; 4^th Clinical Trials Conference, September 11-13, 2017 San Antonio, USA; 15^th World Angiology Meeting, December 08-09, 2016 Philadelphia, USA; 14^th Clinical Cardiology Conference, November 14-16, 2016, Orlando, USA; 14^th Experimental Cardiology Conference, November 14-16, 2016, Orlando, USA; ESMO 2017 Congress, September 08-12, 2017, Madrid, Spain; European Society for Medical Oncology 2016 Congress October, 07-11, 2016 Denmark; ASCO Annual Meeting, June 02-06, 2016, Chicago, USA; 8^th UAE Cancer Congress, October 20-22, 2016, Dubai, UAE; American Thoracic Society Conference, May 19-24, 2017, Washington DC, USA; 17^th World Conference on Lung Cancer December, 04-07, 2016 Austria; 5th Emirates Oncology Conference, November 17-19, 2016, Abu Dhabi, UAE; American Academy of Neurology Annual Meeting April 22-28, 2017, Boston, USA.

Track 6: Biomarkers and Radiology

Even though radiological sciences have long history in the medical field, Imaging Biomarkers have given it a new turn. In the modern day radiology, biomarkers have an undividable integral part which has become the major reason for the latest developments in this field. This biomarker conference places a special session to focus on this area of research.

Imaging biomarkers play a significant and crucial role in the modern day medical imaging. Radiology has forwarded to the present state of development only through the help of imaging biomarkers.

Related Biomarkers Conferences | Cancer Biomarkers Conferences | Molecular Biomarkers Conferences 

Molecular Cardiology Conference, August 31- September 1, 2017, Philadelphia, USA; Interventional Cardiology Conference, August 31- September 1, 2017, Philadelphia, USA; 3^rd Pediatric Cardiology Conference, September 25-27, 2017, Chicago, USA; 13^th European Cardiology Congress, December 05-06, 2016, Madrid, Spain; 11^th World Neurology Congress, March 27-29, 2017, Madrid, Spain; ASCO Annual Meeting, June 02-06, 2016, Chicago, USA; 25th AICR Research Conference, November 14-16, 2016, North Bethesda, USA; National Cancer Institute; 12^th Annual Biomarkers Congress February 21-24, 2017, Manchester, UK; 2^nd Biomarkers Conference February 06-07, 2017, San-Diego, USA; 4^th International Oncology Conference, September 29-30, 2016, Abu Dhabi, UAE; 8^th UAE Cancer Congress, October 20-22, 2016, Dubai, UAE; American Thoracic Society Conference, May 19-24, 2017, Washington DC, USA.

Track 7: Cell Free Biomarkers

Circulating biomarkers allow for the possibility of early, non-invasive detection of cancers. They also represent highly sensitive biomarkers of submissive disease and are capable of reflecting tumour affliction and cancer changing aspects. In the cancer biomarkers conferences, clinical, technical, and biological aspects of cell free biomarkers, and new technologies and techniques will be discussed. Special attention will be given to studies on clinical cases to further see the sights of the applications of these biomarkers and prospective of cell free biomarkers in disease diagnostics.

Circulatory biomarkers, precisely blood biomarkers have a wide area of research with development on various latest techniques, tools and tests for their detection and analysis, specifically aimed on targeted delivery.

Related Biomarkers Conferences | Cancer Biomarkers Conferences | Molecular Biomarkers Conferences

 8^th Biomarkers Conference, December 05-07, 2016 Philadelphia, USA; 9^th Pharmacogenomics Conference, July 13-14, 2017, Chicago, USA; 19^th World Cancer Conference, November 21-23, 2017, London, UK; 6^th Mass Spectrometry Conference, September 25-27, 2017, Atlanta, USA; 5^th Medicinal Chemistry Conference, December 05-07, 2016, Phoenix, USA; ESMO 2017 Congress, September 08-12, 2017, Madrid, Spain; ASCO Annual Meeting, June 02-06, 2016, Chicago, USA; American Society of Clinical Oncology; 12^th Annual Biomarkers Congress February 21-24, 2017, Manchester, UK; 13^th Annual Biomarkers & Diagnostics World Congress May 2-4, 2017, Philadelphia, USA; 8^th UAE Cancer Congress, October 20-22, 2016, Dubai, UAE; Biomarkers & Precision Medicine USA Congress 2016, October 03-04, 2016, San Diego, USA; Next Generation Dx Summit, August 15-18, 2017, Washington DC, USA.

Track 8: Predictive Cancer Biomarkers

Cancer biomarkers have become an indispensable part of cancer patient care. With discovery efforts on-going, the next phase towards conversion will involve validation and verification of clinical value. This includes the steps needed to manage the new treatment model from treating clinical symptoms to targeting genomic pathways. Focus will be given to the use of circulating tumour material to follow patients peripherally, both with known metastatic disease and post-surgery. In these  Biomarkers congress a special importance is given to this field.

Several challenges and solutions for NGS labs, including identifying and prioritizing biomarkers and patient stratification are the topics of high importance to be discussed under this track. Global Biomarkers conferences provide a great platform for to discuss these latest discoveries.

Related Biomarkers Conferences | Cancer Biomarkers Conferences | Molecular Biomarkers Conferences 

9^th Genomics Conference, July 13-14, 2017, Chicago, USA; 7^th Proteomics Conference, October 24-26, 2016, Rome, Italy; 2^nd Cancer Diagnostics Conference, May 8-10, 2017, Barcelona, Spain; 5^th Mass Spectrometry Conference, December 12-14, 2017, Kuala Lumpur, Malaysia; 5^th Computer Aided Drug Designing Conference, December 05-07, 2016, Phoenix, USA; 19^th International Conference on Biomarkers and Clinical Medicine, May 18-19, 2017, Paris, France; 8^th UAE Cancer Congress, October 20-22, 2016, Dubai, UAE; 17^th World Conference on Lung Cancer December, 04-07, 2016 Austria; American Academy of Neurology Annual Meeting April 22-28, 2017, Boston, USA; Biomarkers & Precision Medicine USA Congress 2016, October 03-04, 2016, San Diego, USA; Association for International Cancer Research; European Organisation for Research and Treatment of Cancer; ESMO 2017 Congress, September 08-12, 2017, Madrid, Spain.

Track 9:   Biomarkers Detection & Discovery

Biomarker discovery requires highly assured identification of a biomarker with real-time quantitative information to indicate which proteins are altering to a statistically pertinent degree in response to disease. The discovery of  biomarkers has developed new strategies starting from the initial steps. In the first stage of biomarker discovery proceedings, investigation depends upon mass spectrometry techniques to make unbiased, semiquantitative analysis of changes between healthy and diseased states. The slope of probable biomarkers generated in the discovery stage is to be further substantiated due to the high false positive rate. It is done through supplemental more targeted and quantitative mass spectrometry techniques, such as immuno affinity peptide enrichment.

Under this track, the latest trends in discovery and development of biomarkers and biomarker identification are discussed. There are many new strategies being fashioned in development of biomarkers. In this section advancements of biomarkers in various sectors like clinical biomarkers, paediatric diseases biomarkers, and clinical analysis of NGS samples are covered.

Related Biomarkers Conferences | Cancer Biomarkers Conferences | Molecular Biomarkers Conferences

 4^th Clinical Case Reports Meeting, April 17-19, 2017, Dubai, UAE; 6^th Imaging Conference, October 19-20, 2017, New York, USA; Medical Imaging Conference, October 20-21, 2016 Chicago, USA; 5^th Translational Medicine Conference, November 28-30, 2016, San Francisco, USA; 14^th Global Experts Meeting on Nanomaterials, March 30- 31, 2017, Madrid, Spain; 7^th Personalized Medicine Conference, October 23-25, 2017 Chicago, USA; Association for International Cancer Research; Philippine Cancer Society; European Society for Medical Oncology 2016 Congress October, 07-11, 2016 Denmark; 13^th Annual Biomarkers & Diagnostics World Congress May 2-4, 2017, Philadelphia, USA; 4^th International Oncology Conference, September 29-30, 2016, Abu Dhabi, UAE; 5th Emirates Oncology Conference, November 17-19, 2016, Abu Dhabi, UAE;  4^th Caribbean Biomedical Research Days Conference, January 16-18, 2017, Rodney Bay, St. Lucia; Next Generation Dx Summit, August 15-18, 2017, Washington DC, USA.

Track 10: Biomarkers: Validation and Verification

The probable  Biomarkers identified in discovery section need to be validated by using larger sample sets casing a broad section of patient troops. To avoid a potential bottleneck associated with taking a large number of candidates to validation, a verification step is engaged to monitor potential molecular biomarkers to ensure that only the top quality biomarkers from the discovery phase are taken into the expensive validation stage. A high throughput workflow with a minimum of sample preparation is required in the verification stage which provides both high specificity and high sensitivity. Furthermore, the confirmation that a particular methodology is suitable to be used in the biomarker validation phase is given in verification stage. These advanced strategies can be sited at molecular biomarkers conference.

The main areas covered under this track are Omics Technologies in Biomarkers Discovery and Validation, assessment of drug response, advances in analysis, application of various tools in verification and validation of biomarkers and latest diagnostic techniques. All the latest techniques can be publicized in these biomarkers conferences.

Related Biomarkers Conferences | Cancer Biomarkers Conferences | Molecular Biomarkers Conferences

4^th Clinical Trials Conference, September 11-13, 2017 San Antonio, USA; 14^th Clinical Cardiology Conference, November 14-16, 2016, Orlando, USA; Molecular Cardiology Conference, August 31- September 1, 2017, Philadelphia, USA; 3^rd Pediatric Cardiology Conference, September 25-27, 2017, Chicago, USA; 11^th World Neurology Congress, March 27-29, 2017, Madrid, Spain; European Organisation for Research and Treatment of Cancer; American Association for Cancer Research Annual Meeting April 01-05, 2017, Washington DC, USA; European Society for Medical Oncology 2016 Congress October, 07-11, 2016 Denmark; 2^nd Biomarkers Conference February 06-07, 2017, San-Diego, USA; 4^th International Oncology Conference, September 29-30, 2016, Abu Dhabi, UAE; 17^th World Conference on Lung Cancer December, 04-07, 2016 Austria;  4^th Caribbean Biomedical Research Days Conference, January 16-18, 2017, Rodney Bay, St. Lucia; Biomarkers & Precision Medicine USA Congress 2016, October 03-04, 2016, San Diego, USA.

Track 11: Advances of Biomarker testing

Biomarker testing is a group of tests that looks for the molecular signs of health so that doctors can plan the best care. Biomarker testing can also be called as genetic testing or biomarkers testing.  Biomarkers, a foundation of precision oncology, are very important in management of breast cancer, gastro-esophageal cancer and non-small cell lung cancer. Testing practices are intensely deliberated, influencing diagnostic quality and affecting pathologists, oncologists and patients.

The advances in biomarker testing are mainly in the fields of genetic testing, cancers and other diseases in their diagnosis, treatment and imaging. In silico biomarkers, microRNA biomarkers and several other clinical biomarkers evolved in the recent researches have opened up the path for biomarker testing broader.

Related Biomarkers Conferences | Cancer Biomarkers Conferences | Molecular Biomarkers Conferences

6^th Mass Spectrometry Conference, September 25-27, 2017, Atlanta, USA; 5^th Mass Spectrometry Conference, December 12-14, 2017, Kuala Lumpur, Malaysia; 5^th Medicinal Chemistry Conference, December 05-07, 2016, Phoenix, USA; 5^th Computer Aided Drug Designing Conference, December 05-07, 2016, Phoenix, USA; 3^rd Biopharmaceutics Conference, June 19-21, 2017 Philadelphia, USA; European Society for Medical Oncology 2016 Congress October, 07-11, 2016 Denmark; ASCO Annual Meeting, June 02-06, 2016, Chicago, USA; 25th AICR Research Conference, November 14-16, 2016, North Bethesda, USA; 2^nd Biomarkers Conference February 06-07, 2017, San-Diego, USA; 19^th International Conference on Biomarkers and Clinical Medicine, May 18-19, 2017, Paris, France; 4^th International Oncology Conference, September 29-30, 2016, Abu Dhabi, UAE; 8^th UAE Cancer Congress, October 20-22, 2016, Dubai, UAE; 5th Emirates Oncology Conference, November 17-19, 2016, Abu Dhabi, UAE.

Track 12: Biomarkers and Personalized Medicine

The ability to look at a patient individually will provide a more precise cancer diagnosis and specific treatment plan. The genetic information from individuals can then be used to effectively treat them, by finding the variations that can account for possible diseases. An individual’s genetic make-up also plays a large part in their extent of response to a certain treatment, and hence, having the knowledge of their genetic content can alter the type of treatment they receive. These approaches are intended to identify individualized patient benefits of therapies, minimize the risk of toxicity and reduce the cost of treatment.

In personalized medicine, biomarkers have a special place, which mends with cancer diagnosis, drug development and usage and cancer genomics. Challenges in these fields are an interesting topic to be discussed as there are radiant solutions emerging.

Related Biomarkers Conferences | Cancer Biomarkers Conferences | Molecular Biomarkers Conferences

5^th Medicinal Chemistry Conference, December 05-07, 2016, Phoenix, USA; 5^th Computer Aided Drug Designing Conference, December 05-07, 2016, Phoenix, USA; 3^rd Biopharmaceutics Conference, June 19-21, 2017 Philadelphia, USA; 3^rd Biologic Drugs Conference, June 19-21, 2017 Philadelphia, USA; 3^rd Genetic Engineering Conference, October 30-November 1, 2017, Las Vegas, USA; American Society of Clinical Oncology; Association for International Cancer Research; American Association for Cancer Research Annual Meeting April 01-05, 2017, Washington DC, USA; American Academy of Neurology Annual Meeting April 22-28, 2017, Boston, USA;  4^th Caribbean Biomedical Research Days Conference, January 16-18, 2017, Rodney Bay, St. Lucia; Biomarkers & Precision Medicine USA Congress 2016, October 03-04, 2016, San Diego, USA; 3^rd Annual Drug Discovery USA Congress, 3-4 October 2016, San Diego, USA; Next Generation Dx Summit, August 15-18, 2017, Washington DC, USA.

Track 13: Companion Diagnostics

A medical device, which is often an in vitro device and which offers information that is important for the safe and operative use of a respective drug administration or biological product is called a companion diagnostic. These devices help to determine whether a specific therapeutic product’s benefits to a patient will be of more importance that can overshadow any possible serious side effects or risks to treat a patient. These biomarkers congress invite the latest technologies and techniques to be brought into light.

Partnership between cancer pharmaceutics and diagnostics is a sensitive relation as there are often miscommunications due to lack of knowledge on requirements and feasibilities. The strategies for Rx-Dx partnerships provide a good platform for sharing the knowledge. Development of In-vitro companion diagnostic devices and their commercialization is a rapidly budding area. These diagnostics are useful in the study of surgical oncology.

Related Biomarkers Conferences | Cancer Biomarkers Conferences | Molecular Biomarkers Conferences

  6^th Mass Spectrometry Conference, September 25-27, 2017, Atlanta, USA; 5^th Mass Spectrometry Conference, December 12-14, 2017, Kuala Lumpur, Malaysia; 7^th Molecular Diagnostics Conference, October 23-25, 2017 Chicago, USA; 5^th Translational Medicine Conference, November 28-30, 2016, San Francisco, USA; 14^th Global Experts Meeting on Nanomaterials, March 30- 31, 2017, Madrid, Spain; 19^th International Conference on Biomarkers and Clinical Medicine, May 18-19, 2017, Paris, France; 4^th International Oncology Conference, September 29-30, 2016, Abu Dhabi, UAE; 8^th UAE Cancer Congress, October 20-22, 2016, Dubai, UAE; American Thoracic Society Conference, May 19-24, 2017, Washington DC, USA; 17^th World Conference on Lung Cancer December, 04-07, 2016 Austria; ESMO 2017 Congress, September 08-12, 2017, Madrid, Spain; European Society for Medical Oncology 2016 Congress October, 07-11, 2016 Denmark; ASCO Annual Meeting, June 02-06, 2016, Chicago, USA.

Track 14: Biomarkers and Pharmacology

In the biomarker pipeline, the technologies that will enable the use of biomarkers in drug discovery and development vary depending on the research stage. The second stage, biomarker validation and clinical assay development, depends upon extremely sensitive and specific high-throughput immunoassays. The single greatest challenge in discovering biomarkers with clinical utility is the sensitivity and specificity necessary to determine that a biomarker is truly positive for disease or disease toxicodynamics, and can be used to detect deviations from normal. The  biomarkers congress provide good exposure in drug discovery.

Biomarkers have special applications in the areas of translational medicine, clinical development and safety assessment where they are put through several stages of drug discovery, development and validation.

Related Biomarkers Conferences | Cancer Biomarkers Conferences | Molecular Biomarkers Conferences

 9^th Pharmacogenomics Conference, July 13-14, 2017, Chicago, USA; 6^th Experts Meeting on Medical Case Reports, October 16-18, 2017, San Francisco, USA; 4^th Clinical Trials Conference, September 11-13, 2017 San Antonio, USA; 15^th World Angiology Meeting, December 08-09, 2016 Philadelphia, USA; 11^th World Neurology Congress, March 27-29, 2017, Madrid, Spain; European Society for Medical Oncology 2016 Congress October, 07-11, 2016 Denmark; ASCO Annual Meeting, June 02-06, 2016, Chicago, USA; American Association for Cancer Research Annual Meeting April 01-05, 2017, Washington DC, USA; 12^th Annual Biomarkers Congress February 21-24, 2017, Manchester, UK; 4^th International Oncology Conference, September 29-30, 2016, Abu Dhabi, UAE; 5th Emirates Oncology Conference, November 17-19, 2016, Abu Dhabi, UAE; Biomarkers & Precision Medicine USA Congress 2016, October 03-04, 2016, San Diego, USA; 2^nd Biomarkers Conference February 06-07, 2017, San-Diego, USA.

Track 15: Biomarkers Imaging and Dynamics

Biomarkers Imaging is a cross-discipline which is an intersection of in vivo imaging and biomarkers biology. It facilitates the picturing of the cellular function and the supplement of the molecular process in biological processes without disturbing the living organisms. The various fields of study the Biomarkers Imaging brings life into are diagnosis of diseases such as cancer, cardiovascular diseases and neurological disorders. This technique also donates to the improvisation of the treatment of various diseases and disorders by adjusting the pre-clinical and clinical tests of new drugs. The biomarkers dynamics meetings are also expected to have a major economic impact due to very prior and more precise diagnosis.

Biomarkers imaging techniques using biomarkers popularly known as Imaging biomarkers have an important role in screening in various diseases particularly cancer screening using various new generation tools and technologies. 

Related Biomarkers Conferences | Cancer Biomarkers Conferences | Molecular Biomarkers Conferences

 4^th Clinical Trials Conference, September 11-13, 2017 San Antonio, USA; 15^th World Angiology Meeting, December 08-09, 2016 Philadelphia, USA; 14^th Clinical Cardiology Conference, November 14-16, 2016, Orlando, USA; 14^th Experimental Cardiology Conference, November 14-16, 2016, Orlando, USA; Molecular Cardiology Conference, August 31- September 1, 2017, Philadelphia, USA; National Cancer Institute; 25th AICR Research Conference, November 14-16, 2016, North Bethesda, USA; American Association for Cancer Research Annual Meeting April 01-05, 2017, Washington DC, USA; Biomarkers & Precision Medicine USA Congress 2016, October 03-04, 2016, San Diego, USA; 3^rd Annual Drug Discovery USA Congress, 3-4 October 2016, San Diego, USA; 4^th International Oncology Conference, September 29-30, 2016, Abu Dhabi, UAE; 8^th UAE Cancer Congress, October 20-22, 2016, Dubai, UAE; American Thoracic Society Conference, May 19-24, 2017, Washington DC, USA.

Track 16: Oncologists

The study of cancer is called Oncology. An oncologist is a person who specializes in the area of oncology and treating cancer patients. An oncologist manages care and treatment once a person is diagnosed with cancer.

In Germany there are about 2900 oncologists, and more than 8000 oncologists in USA, around 9500 oncologists in Europe and 1500 eminent oncologists from different parts of Asia.

Related Biomarkers Conferences | Cancer Biomarkers Conferences | Molecular Biomarkers Conferences

Medical Imaging Conference, October 20-21, 2016 Chicago, USA; 6^th Radiology Conference, October 19-20, 2017, New York, USA; 6^th Imaging Conference, October 19-20, 2017, New York, USA; 5^th Euro-Global Experts Meeting on Medical Case Reports, September 7-9, 2017, Paris, France; 4^th Clinical Case Reports Meeting, April 17-19, 2017, Dubai, UAE; American Society of Clinical Oncology; 4^th International Oncology Conference, September 29-30, 2016, Abu Dhabi, UAE; 8^th UAE Cancer Congress, October 20-22, 2016, Dubai, UAE; 5th Emirates Oncology Conference, November 17-19, 2016, Abu Dhabi, UAE; 12^th Annual Biomarkers Congress February 21-24, 2017, Manchester, UK; 19^th International Conference on Biomarkers and Clinical Medicine, May 18-19, 2017, Paris, France.

Track 17: Case Reports

A case report is an elaborated report of the symptoms, signs, disease diagnosis, treatment, and follow-up of an individual patient usually recorded in medical field. Case reports might comprehend a demographic profile of the patient, but typically mention any unusual or unique occurrences.

In this conference case reports on biomarker diagnostics, drug discovery and imaging are discussed in detail in relevance to molecular and cancer biomarkers. Cancer biomarkers conferences are a big platform to study case reports of these in precision. 

Related Biomarkers Conferences | Cancer Biomarkers Conferences | Molecular Biomarkers Conferences

4^th Clinical Case Reports Meeting, April 17-19, 2017, Dubai, UAE; 6^th Experts Meeting on Medical Case Reports, October 16-18, 2017, San Francisco, USA; 4^th Clinical Trials Conference, September 11-13, 2017 San Antonio, USA; 15^th World Angiology Meeting, December 08-09, 2016 Philadelphia, USA; 14^th Clinical Cardiology Conference, November 14-16, 2016, Orlando, USA; American Association for Cancer Research Annual Meeting April 01-05, 2017, Washington DC, USA; ESMO 2017 Congress, September 08-12, 2017, Madrid, Spain; European Society for Medical Oncology 2016 Congress October, 07-11, 2016 Denmark; 17^th World Conference on Lung Cancer December, 04-07, 2016 Austria; 5th Emirates Oncology Conference, November 17-19, 2016, Abu Dhabi, UAE; American Academy of Neurology Annual Meeting April 22-28, 2017, Boston, USA;  4^th Caribbean Biomedical Research Days Conference, January 16-18, 2017, Rodney Bay, St. Lucia; Biomarkers & Precision Medicine USA Congress 2016, October 03-04, 2016, San Diego, USA.

Track 18: Entrepreneurs Investment Meet

Self-knowledge is the key ingredient in successful entrepreneurship.  Biomarkers congress aim to bring together all existing and promising bio entrepreneurs to share capabilities and present new novelties and challenges in biomarker community. Over a million companies are started in the world each year, in which about 5–10 of them are classified into high technology companies. All the Pharmaceutical and Biotech companies are majorly involved in the biomarkers production. Whirling ideas into business ventures is complex and the opportunity appreciation step is critical in new project creation. This idea in the entrepreneur's perception of the association between the invention and final product is converted into a business prototype that describes how the venture generate revenue or provide an suitable yield to the prospective investors. Clinical Research on biomarkers is multifaceted and rapidly expanding and requires an expert knowledge to comprehend the value of the advances and its competitive situation in the industry. Even though scientists are stereotypically the founders of biotech companies, studies indicate that the most effective start-ups are founded by a team which often has two to three individuals with mixed backgrounds like clinical research and Clinical Data Management along with considerable industry experience and a very strong market and product focus at establishment. This two day world-wide molecular and cancer biomarkers conferences will be a highly interactive forum that will bring experts in highly significant areas ranging from Biomarker discovery to latest diagnostics and Rx-Dx relationships. This global biomarker conferences is sure a great platform to discuss the strategized development of industrial production of biomarkers.  

Related Biomarkers Conferences | Cancer Biomarkers Conferences | Molecular Biomarkers Conferences

 8^th Biomarkers Conference, December 05-07, 2016 Philadelphia, USA; Biomarkers & Immuno-Oncology World Congress May 2-4,2017, Philadelphia, PA 9^th Genomics Conference, July 13-14, 2017, Chicago, USA; 9^th Pharmacogenomics Conference, July 13-14, 2017, Chicago, USA; 7^th Proteomics Conference, October 24-26, 2016, Rome, Italy; 19^th World Cancer Conference, November 21-23, 2017, London, UK; ESMO 2017 Congress, September 08-12, 2017, Madrid, Spain; European Society for Medical Oncology 2016 Congress October, 07-11, 2016 Denmark; ASCO Annual Meeting, June 02-06, 2016, Chicago, USA; 4^th International Oncology Conference, September 29-30, 2016, Abu Dhabi, UAE; 13^th Annual Biomarkers & Diagnostics World Congress May 2-4, 2017, Philadelphia, USA; 12^th Annual Biomarkers Congress February 21-24, 2017, Manchester, UK; Biomarkers & Precision Medicine USA Congress 2016, October 03-04, 2016, San Diego, USA; 5^th Emirates Oncology Conference, November 17-19, 2016, Abu Dhabi, UAE.

The global market for cancer biomarkers was estimated to grow from $3.6 billion to $29.78 billion from 2007 by 2018 at an expected 14.60% CAGR (Compounded Annual Growth Rate) from 2011 when it was at $13.16 billion. Various factors such as the increasing demand for personalized medicine and companion diagnostics have enlarged the utility of biomarkers in the healthcare sector.

Biomarkers are any measurable characteristics of an organism that reflect a particular physiological state. In medicine, biomarkers are used as an indicator to find the disease presence or its severity. Biomarker research has gone further to new drug therapies, companion diagnostics and many other versatile fields. Demand for new biomarkers in different applications has boosted the biomarkers market.

Birmingham is one of the leading biomarker research centres in Europe. UK has good number of industries and research labs which work on biomarkers in various fields along with commercial production of them.

Members associated with Biomarker research:

 Biomarker research is widely encouraged all over the world. Experts from various cross disciplines like oncology, pathology, proteomics, genomics, pharmacologists, doctors, clinicians and technology enlargement industries working in the field of biomarkers. 

Hospitals associated with Biomarker research:

Various institutes and treatment facilities involved in cancer research and are intricate in cancer biomarker research all around the world. There are about 3976 hospitals in the world and 272 hospitals in UK which are prominent and working on biomarkers.

Societies associated with Biomarker research:

Biomarkers and cancer biomarkers are used in several disease diagnosis and treatment. Many eminent societies, associations and organizations are also taking part in the biomarker research. Some of them are,

• Alzheimer's Association
• American Brain Tumor Association
• American Society of Clinical Oncology
• Association for Molecular Pathology
• Cancer Research Society
• Cancer Research UK
• German Society for Oncological Pharmacy
• National Cancer Institute at the National Institutes of Health
• The ALS Association
• The British Association for Cancer Research
• The Canadian Cancer Society
• The International Society Of Oncology and Biomarkers
• The Swedish Cancer Society

Industries associated with Biomarker research:

Biomarkers are not permitted to labs but actually produced in commercial scale by many industries and used in prognosis, diagnosis, treatment etc.

Companies which play an important role in biomarker market in UK are,

• abcodia
• Blue Earth Diagnostics
• Erba MDX (Erba)
• Oxford Cancer Biomarkers
• ValiRx

Companies from all over the world are,

• 20/20 Gene Systems
• Curetis
• IntegraGen
• Nuclea Biotechnologies
• ProteoMediX

Universities associated with Biomarker research:

The majority of research is conducted in educational institutions by passionate groups of researches in numerous places throughout the world.

The top universities in Birmingham are,

• Abbey College Birmingham
• Aston University
• Matthew Boulton College
• University of Birmingham Medical School
• South & City College Birmingham

The top universities from rest of the world are,

• Stanford University
• Harvard University
• University of California, Los Angeles
• Yale University
• Weill Cornell Medicine

Market value on Biomarkers:

The present global market value of biomarkers is estimated to be $33 billion.

Nearly $7.32 billion is spent on the biotech industry in Europe in R&D and has $23.2 billion in revenue. About 20% of the total medicines marketed and almost 50% of all drugs in the pipeline are all products of healthcare biotech. About 95,000 people are provided employment by European biotech industry contributing to EU policies. When compared to the other EU members, UK accommodates maximum number of biotech-based companies which makes it the leading player in this market.

Market Growth

From $29.3 billion in 2013, the biomarkers market is anticipated to grow up to $53.6 billion in 2018, a compound annual growth rate (CAGR) of 12.8%.

In 2008 the UK pharmaceuticals market valued $54.7 billion and is expected to reach an approximate value of $65 billion by 2020 at a CAGR of 1.4%. The medical device market of UK was worth $18.9 billion in 2008 and is assessed to reach $34.4 billion in 2020 at a CAGR of 5.1%. 

Products manufactured by the industries related to Biomarker Research and its market Value:

Numerous products are produced by industries for various uses like CTC technology, RNAi research tools, diagnostic tests and tools, separation systems and several other kits. These biomarker products have demanding market now. Some of them are having a great market value up to $17.1 billion and are expected to rise to $27.8 billion in near future. 

Fund Allotment to Biomarker Research:

The Biomarker research has increased in double fold since it was first mentioned in 1973 in a research paper, also the funds allocated increased accordingly. NIH gave nearly $10.7 billion worth of grants to roughly 30,000 studies related to biomarker research, in which 10% are dedicated to just validation of biomarkers alone.

Other companies also funding the research with the increased market value. For example, a developer of novel prenatal screening tests company, Natera just announced an IPO with a $100 million goal. Natera’s revenue is $47.4 million, which raised from $27.2 million in 2014. Developers of novel cancer tests, Foundation Medicine, recently received an investment from Roche that increased the value of company over $2 billion.

Statistics of Physicians, Researchers and Academicians working on Biomarker Research:

The main individuals working on Biomarkers are academicians, researchers and physicians. There are plenty of people working on the biomarker research. In Birmingham alone there are 80 prominent persons working on biomarkers. There are about 5000 people In UK and about 40,000 eminent persons totally doing research related to biomarkers.

Title: 9th World Biomarkers Congress

Date: December 07-08, 2017

Venue: Madrid, Spain

Theme: Biomarkers: A New Era of Diagnosis and Clinical Research

Key Topics of Discussion